Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States
ConclusionOral semaglutide was associated with lower cost of bringing patients with type 2 diabetes to four clinically-relevant treatment targets versus empagliflozin, sitagliptin, and liraglutide in the US.FundingNovo Nordisk A/S.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Empagliflozin | Endocrinology | Januvia | Jardiance | Study | USA Health | Victoza | Weight Loss